Microarray Profiling of Antibody Responses against Simian-Human Immunodeficiency Virus: Postchallenge Convergence of Reactivities Independent of Host Histocompatibility Type and Vaccine Regimen
暂无分享,去创建一个
Lawrence Steinman | W. Robinson | L. Steinman | P. Utz | H. Robinson | R. Amara | William H. Robinson | Paul J. Utz | Rama Rao Amara | Harriet L. Robinson | Henry E. Neuman de Vegvar | H. E. Neuman de Vegvar
[1] Control of a Mucosal Challenge and Prevention of AIDS by a Multiprotein DNA/MVA Vaccine , 2001, Science.
[2] D. Grandgenett,et al. Folding of the multidomain human immunodeficiency virus type‐I integrase , 1994, Protein science : a publication of the Protein Society.
[3] K. Sepkowitz,et al. AIDS--the first 20 years. , 2001, The New England journal of medicine.
[4] J. Sodroski,et al. Persistent infection of macaques with simian-human immunodeficiency viruses , 1995, Journal of virology.
[5] A. Simon,et al. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. , 2000, Science.
[6] Ali Ahmad,et al. Antibody‐dependent cellular cytotoxicity in HIV infections , 1996, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[7] R. M. Hendry,et al. High prevalence of antibodies to the gp120 V3 region principal neutralizing determinant of HIV-1MN in sera from Africa and the Americas. , 1991, AIDS research and human retroviruses.
[8] D. Burton. Antibodies, viruses and vaccines , 2002, Nature Reviews Immunology.
[9] R. Kennedy,et al. Antiserum to a synthetic peptide recognizes the HTLV-III envelope glycoprotein. , 1986, Science.
[10] P. Brown,et al. Protein microarrays for highly parallel detection and quantitation of specific proteins and antibodies in complex solutions , 2001, Genome Biology.
[11] J. Mascola,et al. Correlation between humoral responses to human immunodeficiency virus type 1 envelope and disease progression in early-stage infection. , 1998, The Journal of infectious diseases.
[12] B. Walker,et al. CD8+ cells in human immunodeficiency virus type I pathogenesis: cytolytic and noncytolytic inhibition of viral replication. , 1997, Advances in immunology.
[13] M. Cohn,et al. The Protection: The Unit of Humoral Immunity Selected by Evolution , 1990, Immunological Reviews.
[14] S. Pincus,et al. Effect of nonprotective vaccination on antibody response to subsequent human immunodeficiency virus infection. , 1994, The Journal of clinical investigation.
[15] M. Bukrinsky,et al. Association of integrase, matrix, and reverse transcriptase antigens of human immunodeficiency virus type 1 with viral nucleic acids following acute infection. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[16] G. Altavilla,et al. HIV type 1 extracellular Tat protein stimulates growth and protects cells of BK virus/tat transgenic mice from apoptosis. , 1995, AIDS research and human retroviruses.
[17] S. Zolla-Pazner,et al. Epitope mapping of two immunodominant domains of gp41, the transmembrane protein of human immunodeficiency virus type 1, using ten human monoclonal antibodies , 1991, Journal of virology.
[18] J. Sodroski,et al. Characterization of molecularly cloned simian-human immunodeficiency viruses causing rapid CD4+ lymphocyte depletion in rhesus monkeys , 1997, Journal of virology.
[19] P. Earl,et al. Different Patterns of Immune Responses but Similar Control of a Simian-Human Immunodeficiency Virus 89.6P Mucosal Challenge by Modified Vaccinia Virus Ankara (MVA) and DNA/MVA Vaccines , 2002, Journal of Virology.
[20] H. M. Geysen,et al. Use of peptide synthesis to probe viral antigens for epitopes to a resolution of a single amino acid. , 1984, Proceedings of the National Academy of Sciences of the United States of America.
[21] L. Gritz,et al. Production and of monoclonal antibodies to simian immunodeficiency virus envelope glycoproteins. , 1991, AIDS.
[22] F. Alt,et al. Development of the primary antibody repertoire. , 1987, Science.
[23] J. Nelson,et al. Diagnosis of AIDS by using a 12-amino acid peptide representing an immunodominant epitope of the human immunodeficiency virus. , 1987, The Journal of infectious diseases.
[24] N. Haigwood,et al. Neutralizing antibody directed against the HIV–1 envelope glycoprotein can completely block HIV–1/SIV chimeric virus infections of macaque monkeys , 1999, Nature Medicine.
[25] C. Y. Wang,et al. Detection of antibodies to human T-lymphotropic virus type III by using a synthetic peptide of 21 amino acid residues corresponding to a highly antigenic segment of gp41 envelope protein. , 1986, Proceedings of the National Academy of Sciences of the United States of America.
[26] J. Mascola,et al. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies , 2000, Nature Medicine.
[27] B. Walker,et al. Anti-HIV cellular immunity: recent advances towards vaccine design. , 1999, AIDS.
[28] John D. Storey. A direct approach to false discovery rates , 2002 .
[29] B. Walker,et al. HIV Molecular Immunology 2001 , 2001 .
[30] C. Hanson,et al. Evaluation of monoclonal antibodies to HIV-1 by neutralization and serological assays: an international collaboration. Collaborating Investigators. , 1991, AIDS.
[31] R. Brasseur,et al. Map of sequential B cell epitopes of the HIV-1 transmembrane protein using human antibodies as probe. , 1990, Intervirology.
[32] H. Robinson,et al. A new generation of HIV vaccines. , 2002, Trends in molecular medicine.
[33] Q. Sattentau,et al. The neutralizing antibody response to HIV-1: viral evasion and escape from humoral immunity. , 1999, AIDS.
[34] Tahir A. Rizvi,et al. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian–human immunodeficiency virus infection , 2000, Nature Medicine.
[35] R. Tibshirani,et al. Significance analysis of microarrays applied to the ionizing radiation response , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[36] B. Graham,et al. Vaccine-specific antibody responses induced by HIV-1 envelope subunit vaccines. , 1997, Journal of Immunology.
[37] P. Brown,et al. Autoantigen microarrays for multiplex characterization of autoantibody responses , 2002, Nature Medicine.
[38] P. Earl,et al. Critical Role for Env as well as Gag-Pol in Control of a Simian-Human Immunodeficiency Virus 89.6P Challenge by a DNA Prime/Recombinant Modified Vaccinia Virus Ankara Vaccine , 2002, Journal of Virology.
[39] A. Coutinho,et al. Functional diversity and clonal frequencies of reactivity in the available antibody repertoire , 1998, European journal of immunology.
[40] W. Blattner,et al. Differences in the antibody response to human immunodeficiency virus-1 envelope glycoprotein (gp160) in infected laboratory workers and vaccinees. , 1993, The Journal of clinical investigation.
[41] S. Lemon,et al. Immunogenic domains of hepatitis delta virus antigen: peptide mapping of epitopes recognized by human and woodchuck antibodies , 1990, Journal of virology.
[42] L. van der Hoek,et al. Immunodominance and antigenic variation of the principal neutralization domain of HIV-1. , 1991, Virology.
[43] D. Botstein,et al. Cluster analysis and display of genome-wide expression patterns. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[44] J. Moore,et al. Epitope mapping and topology of baculovirus-expressed HIV-1 gp160 determined with a panel of murine monoclonal antibodies. , 1994, AIDS research and human retroviruses.
[45] J. Hilliard,et al. Identification of a herpes B virus-specific glycoprotein d immunodominant epitope recognized by natural and foreign hosts. , 2002, The Journal of infectious diseases.
[46] J. Hurwitz,et al. Effect of natural HIV-1 envelope V1-V2 sequence diversity on the binding of V3-specific and non-V3-specific antibodies. , 1997, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.
[47] J. Sodroski,et al. A chimeric simian/human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate env causes an AIDS-like disease after in vivo passage in rhesus monkeys , 1996, Journal of virology.
[48] K. Okuda,et al. Recognition of prominent viral epitopes induced by immunization with human immunodeficiency virus type 1 regulatory genes , 1997, Journal of virology.
[49] A. von Brunn,et al. Principal neutralizing domain of HIV-1 is highly immunogenic when expressed on the surface of hepatitis B core particles. , 1993, Vaccine.
[50] R. Weiss,et al. An engineered poliovirus chimaera elicits broadly reactive HIV-1 neutralizing antibodies , 1989, Nature.